Ingevity Corporation filed a Form 8-K with the SEC on November 4, 2026, announcing preliminary financial results for the three and nine months ended September 30, 2026, with the full results attached as a press release exhibit.
Wolfspeed, Inc. filed a Form 8-K with the SEC on November 4, 2026, announcing the release of its fiscal first quarter results for the period ended September 27, 2026.
Bowman Consulting Group Ltd. filed a Form 8-K on November 4, 2026, reporting the voting results from a virtual special meeting of stockholders held that same day, at which stockholders approved the proposed merger with an affiliate of Bernhard Capital Partners.
Unisys Corporation filed a Form 8-K with the U.S. Securities and Exchange Commission on November 4, 2026, reporting the issuance of a news release covering its financial results for the quarter ended September 30, 2026.
Eversource Energy filed a Form 8-K on November 4, 2026, announcing unaudited results of operations for the third quarter and nine months ended September 30, 2026, along with related financial information for certain of its subsidiaries.
Ingram Micro Holding Corporation filed a Form 8-K on November 4, 2026, disclosing an underwriting agreement dated November 2, 2026, under which selling stockholder Ingram Holdco, LLC agreed to sell 11,000,000 shares of common stock to Goldman Sachs & Co. LLC, with the underwriter's …
Aflac Incorporated filed a Form 8-K with the U.S. Securities and Exchange Commission on November 4, 2026, reporting its third quarter 2026 financial results and furnishing related investor materials.
Franklin Covey Co. filed a Form 8-K on November 4, 2026, announcing its financial results for the fourth quarter and fiscal year ended August 31, 2026, with an earnings release furnished as an exhibit and a shareholder discussion scheduled for the same day.
Citius Oncology, Inc. filed a Form 8-K on November 4, 2026, announcing that it issued a press release presenting health-related quality of life results from pivotal Study 302 of LYMPHIR (denileukin diftitox-cxdl) at the EORTC-CLTG 2026 Annual Meeting.
Xperi Inc. filed a current report on November 4, 2026, disclosing third-quarter 2026 financial results and announcing a planned transition of its Chief Financial Officer role.